AbbVie (ABBV) looks to new drugs to boost sales following Humira competition - WSJ
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to AbbVie (ABBV) looks to new drugs to boost sales following Humira competition - WSJ
February 6, 2023 8:33 AM EST
By Peter Nurse
Investing.com -- Stocks in focus in premarket trade on Monday, February 6th. Please refresh for updates.
Dell Technologies (NYSE: DELL) stock rose 1.5% after Bloomberg reported that the tech company was planning on slashing around 6,650 jobs, or about 5% of its global... More
February 6, 2023 7:05 AM EST
AbbVie (NYSE: ABBV) is looking to two newer immune drugs to offset Humira generic competition and is lifting a self-imposed $2 billion limit on the size of potential deals it could be targeting, the Wall Street Journal reported
...
More
February 6, 2023 6:39 AM EST
BMO Capital analyst Gary Nachman lowered the price target on Abbvie (NYSE: ABBV) to $167.00 (from $169.00) while maintaining a Outperform rating.... More
February 6, 2023 6:35 AM EST
(Reuters) - Abbvie will lift a self-imposed $2 billion limit on acquisitions and mergers placed following a $63 billion deal for Botox maker Allergan in 2020 that shot up its debt, the company's chief executive officer told the Wall Street Journal.
Chief Executive Officer Richard Gonzalez said the company now has the... More
